Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 29;15(1):14979.
doi: 10.1038/s41598-025-98692-8.

Prostate microcalcification crystallography as a marker of pathology

Affiliations

Prostate microcalcification crystallography as a marker of pathology

Sarah B Gosling et al. Sci Rep. .

Abstract

Prostate cancer remains the most common male cancer; however, treatment regimens remain unclear in some cases due to a lack of agreement in current testing methods. Therefore, there is an increasing need to identify novel biomarkers to better counsel patients about their treatment options. Microcalcifications offer one such avenue of exploration. Microfocus spectroscopy at the i18 beamline at Diamond Light Source was utilised to measure X-ray diffraction and fluorescence maps of calcifications in 10 µm thick formalin fixed paraffin embedded prostate sections. Calcifications predominantly consisted of hydroxyapatite (HAP) and whitlockite (WH). Kendall's Tau statistics showed weak correlations of 'a' and 'c' lattice parameters in HAP with GG (rτ = - 0.323, p = 3.43 × 10-4 and rτ = 0.227, p = 0.011 respectively), and a negative correlation of relative zinc levels in soft tissue (rτ = - 0.240, p = 0.022) with GG. Negative correlations of the HAP 'a' axis (rτ = - 0.284, p = 2.17 × 10-3) and WH 'c' axis (rτ = - 0.543, p = 2.83 × 10-4) with pathological stage were also demonstrated. Prostate calcification chemistry has been revealed for the first time to correlate with clinical markers, highlighting the potential of calcifications as biomarkers of prostate cancer.

Keywords: Biomarkers; Calcification; Prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The project was approved by the NRES Committee North West—Haydock (Ref: 25/NW/0013) under the Research Tissue Bank ethical approval of the Human Biomaterials Resource Centre, and all analyses were conducted in accordance with relevant regulations. Informed Consent was collected from all the individuals and is held by the Human Biomaterials Resource Centre for the samples analysed. The study was conducted in accordance with the Declaration of Helsinki. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Diffractograms of examples of mineral phases in prostate calcifications. (a) Standard patterns for calcium phosphate mineral phases, hydroxyapatite and whitlockite, plus example diffractograms of three calcifications containing only hydroxyapatite (Calc 1), a mixture of hydroxyapatite and whitlockite (Calc 2) and only whitlockite (Calc 3). (b) Standard patterns for calcium carbonate mineral phases, aragonite and calcite, and example diffractograms of two calcifications containing calcite and aragonite (Calc 4) and only calcite (Calc 5). A diffractogram of paraffin is also included as this accounts for some of the diffraction peaks observed in the data due to the use of FFPE tissue. (c) A standard pattern of dorfmanite plus an example calcification containing this mineral phase (Calc 6).
Fig. 2
Fig. 2
Comparison of calcification crystallography in different prostatic zones. (a) Average diffractograms for each prostatic zone, and standard patterns of hydroxyapatite and paraffin. (b) Box plot of HAP ‘c’ axis in calcifications in the different prostatic zones. Each point represents the average measurement for an individual calcification. PZ: Peripheral zone, CZ/TZ: Central/Transition zones, FMZ: Fibromuscular zone, HAP: hydroxyapatite. **p < 0.01.
Fig. 3
Fig. 3
Crystallographic parameters of HAP and WH and zinc distribution averaged by calcification then by grade group (ISUP Grade Groups (GG) 1–5). (a and b) ‘a’ and ‘c’ axis values for HAP, (c and d) ‘a’ and ‘c’ axis values for WH. ‘a’ and ‘c’ axes represent physical dimensions of crystal units and can indicate ion substitutions. (e and f) CL measured along 002 and 030 for HAP, (g and h) CL measured along 0210 and 220 for WH. (i and j) Relative zinc levels in prostate calcifications and surrounding soft tissue, measured against total metal ion content (calcium, zinc and iron), presented as a ratio (0–1). Each point represents the average measurement for an individual calcification. HAP: hydroxyapatite, WH: whitlockite, CL: coherence length (a measure of crystallinity in a given direction in a crystal). *p < 0.05, **p < 0.01, ***p < 0.001.
Fig. 4
Fig. 4
Crystallographic parameters of HAP and WH and zinc distribution averaged by calcification then by pathological stage (size or area of cancer, from inside the prostate gland (T2) to local spread (T4)). (a and b) ‘a’ and ‘c’ axis values for HAP, (c and d) ‘a’ and ‘c’ axis values for WH. ‘a’ and ‘c’ axes represent physical dimensions of crystal units, and can indicate ion substitutions. (e and f) CL measured along 002 and 030 for HAP, (g and h) CL measured along 0210 and 220 for WH. (i and j) Relative zinc levels in prostate calcifications and surrounding soft tissue, measured against total metal ion content (calcium, zinc and iron), presented as a ratio (0–1). Each point represents the average measurement for an individual calcification. HAP: hydroxyapatite, WH: whitlockite, CL: coherence length (a measure of crystallinity in a given direction in a crystal). *p < 0.05, **p < 0.01.

Similar articles

References

    1. Cancer Research UK. Prostate Cancer Statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/s... (2024).
    1. Cooperberg, M. R., Broering, J. M. & Carroll, P. R. Time trends and local variation in primary treatment of localized prostate cancer. J. Clin. Oncol.28, 1117–1123 (2010). - PMC - PubMed
    1. Rouviere, O. & Moldovan, P. C. The current role of prostate multiparametric magnetic resonance imaging. Asian J. Urol.6, 137–145 (2019). - PMC - PubMed
    1. Willis, S. R. et al. Multiparametric MRI followed by targeted prostate biopsy for men with suspected prostate cancer: A clinical decision analysis. BMJ Open4, e004895–e004895 (2014). - PMC - PubMed
    1. Gosling, S. B. et al. Microcalcification crystallography as a potential marker of DCIS recurrence. Sci. Rep.13, 9331 (2023). - PMC - PubMed

LinkOut - more resources